Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06116565
PHASE2
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
Sponsor: Keymed Biosciences Co.Ltd
View on ClinicalTrials.gov
Summary
This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.
Official title: An Multi-center, Open-label, Single-arm Phase 2 Study to Evaluate the Long-term Safety and Efficacy of CM310 in Subjects With Moderate-to-severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
263
Start Date
2023-12-21
Completion Date
2025-11-26
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
CM310
CM310, subcutaneous injection
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China